Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Phase 2
500
about 3 years
18+
27 sites in CA, CT, FL +12
About this study
This trial is testing whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) works in treating patients with solid tumor cancers that have high expression of the Trop-2, nectin-4, or HER2 proteins. The goal is to determine if personalized treatment with sacituzumab govitecan, enfortumab vedotin, or trastuzumab deruxtecan may be an effective option for patients with advanced or metastatic solid tumors that screen positive for high expression of Trop-2, nectin-4, or HER2, respectively.
Based on ClinicalTrials.gov records.
What participants do
- 1.Electronic Health Record Review
- 2.Immunohistochemistry Staining Method
- 3.Receive Sacituzumab Govitecan
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
enfortumab vedotin, sacituzumab govitecan, trastuzumab deruxtecan
infusion
Primary: Frequency of high protein expression in patients with high ribonucleic acid (RNA) expression of each antibody-drug conjugate target (screening protocol), Objective response rate (treatment cohorts)
Secondary: Incidence of adverse events (treatment cohorts), Overall survival (treatment cohorts), Pharmacodynamic changes in the tumor and microenvironment (treatment cohorts), Progression free survival (treatment cohorts), Time to progression (treatment cohorts)
biopsy, diagnostic, imaging